PHARMACOLOGICAL TREATMENT OF OSTEOPOROSIS IN PATIENTS WITH CORONARY HEART DISEASE COMPLICATED BY CHRONIC HEART FAILURE

МARIYA  MARUSHCHAK; Inna Krynytska

doi:10.22159/ajpcr.2019.v12i1.29293

Authors

МARIYA MARUSHCHAK Department of Functional and Laboratory Diagnostics, I. Horbachevsky Ternopil State Medical University, Ukraine.
Inna Krynytska Department of Functional and Laboratory Diagnostics, I. Horbachevsky Ternopil State Medical University, Ukraine.

DOI:

https://doi.org/10.22159/ajpcr.2019.v12i1.29293

Keywords:

Chronic heart failure, Osteopenia, Osteoporosis, Therapy

Abstract

Objective: Chronic heart failure (CHF) is a chronic multisystem disorder associated with a myriad of metabolic disturbances. Moreover, CHF may adversely affect bone metabolism and induce a severe bone loss, increasing susceptibility to fractures and osteoporosis. This study investigates the effect of combined calcium with Vitamin D3 supplement called calcemin advanceâ€ and calcitonin in the prophylaxis and treatment of osteopenia and osteoporosis in patients with coronary heart disease (CHD) complicated by CHF with the establishment of their influence on the bone mineral density (BMD).

Methods: A total of 59 patients with CHD complicated by CHF. Interventions: The physical examination findings, dual-energy X-ray absorptiometry findings, and treatment results were assessed.

Results: The results of the calcemin advance usage in patients with osteopenic changes showed a positive dynamics of the studied parameters, both in the lumbar spine and in the femoral bone. In patients with osteoporosis, the usage of osteoprotective therapy (calcemin advance+miacalcic) contributed to the increasing of BMD in the lumbar spine and in the femoral bone versus patients who received only combined calcium with Vitamin D3 supplement.

Conclusions: Our results suggest that bone density screening could be recommended in patients with prevalent CHF. Moreover, the results of our investigation substantiate the necessity and effectiveness of osteoprotective therapy in patients with CHF with osteoporosis by calcitonin (Miacalcic), in combination with combined calcium and Vitamin D3 supplement (calcemin advance), and by only calcemin advance - in patients with CHF and osteopenia.

Downloads

Download data is not yet available.

References

Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, et al. Heart disease and stroke statistics-2018 update: A report from the American heart association. Circulation 2018;137:e67-e492.

Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: The sixth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European association for cardiovascular prevention and rehabilitation (EACPR). Eur Heart J 2016;37:2315-81.

Logoyda L. A HPLC-MS/MS method development and validation for the simultaneous determination of nifedipine and enalapril in human plasma. Int J Appl Pharm 2018;10:35-42.

Stewart J, Manmathan G, Wilkinson P. Primary prevention of cardiovascular disease: A review of contemporary guidance and literature. JRSM Cardiovasc Dis 2017;6:2048004016687211.

Mozaffarian D. Global scourge of cardiovascular disease: Time for health care systems reform and precision population health. J Am Coll Cardiol 2017;70:26-8.

Demikhova N, Chernatska O, Mazur T, Bokova S, Rudenko T, Bumeister L, et al. Markers of cardiovascular complications in patients with Type 2 diabetes mellitus and arterial hypertension. Bangladesh J Med Sci 2018;17:319-22.

Som S. Deficiencies in global health training for cardiovascular fellows. J Am Coll Cardiol 2017;69:1748-52.

Ezekowitz JA, Oâ€™Meara E, McDonald MA, Abrams H, Chan M, Ducharme A, et al. 2017 comprehensive update of the canadian cardiovascular society guidelines for the management of heart failure. Can J Cardiol 2017;33:1342-433.

FarrÃ© N, Vela E, ClÃ¨ries M, Bustins M, Cainzos-Achirica M, Enjuanes C, et al. Real world heart failure epidemiology and outcome: A population-based analysis of 88,195 patients. PLoS One 2017;12:e0172745.

Chen M, Xue L, Cha C, Liang J, Ma P. Impact of strengthening clinical management and intervention on prognosis and compliance among patients with heart failure. Biomed Res 2017;28:5751-7.

Xing W, Lv X, Gao W, Wang J, Yang Z, Wang S, et al. Bone mineral density in patients with chronic heart failure: A meta-analysis. Clin Interv Aging 2018;13:343-53.

Schulz E, Arfai K, Liu X, Sayre J, Gilsanz V. Aortic calcification and the risk of osteoporosis and fractures. J Clin Endocrinol Metab 2004;89:4246-53.

Marushchak M, Krynytska I, Mikolenko A, Andreychyn Y, Bodnar Y, Chornomydz I. Chronic heart failure causes osteopathy or is osteopathy a factor in development of chronic heart failure? Asian J Pharm Clin Res 2018;11:111-5.

Krynytska I, Marushchak M, Zaets T, Savchenko I, Habor H. Investigation of bone mineralization in patients with coronary heart disease complicated by chronic heart failure, stage II-A. Georgian Med News 2017;267:43-8.

Smiyan SI, Masik OM, Zhulkevych IV. Indicators of bone mineraldensity of healthy men on the results of dual energy X-ray densitometry. Probl Osteol 2002;2:9-16.

Hutomo DI, Masulili SL, Tadjoedin FM, Kusdhany LS. Correlation of serum osteocalcin level and periodontal attachment loss with osteoporosis risk status in postmenopausal women. Int J Appl Pharm 2017;9:92-4.

Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006;17:1726-33.

Lian XL, Zhang YP, Li X, Jing LD, Cairang ZM, Gou JQ, et al. Exploration on the relationship between the elderly osteoporosis and cardiovascular disease risk factors. Eur Rev Med Pharmacol Sci 2017;21:4386-90.

Khrystyna P, Liudmyla P, Halyna S, Miz A, Mariya M, Inna K. Investigation of calcium metabolism in patients with coronary heart disease complicated by chronic heart failure, stage ii-a. Bangladesh J Med Sci 2018;17:395-401.

Lewiecki EM, Silverman SL. Redefining osteoporosis treatment: Who to treat and how long to treat. Arq Bras Endocrinol Metabol 2006;50:694-704.

Li S, Ou Y, Zhang H, Zhang Z, Zhou H, Liu L, et al. Vitamin D status and its relationship with body composition, bone mineral density and fracture risk in urban central South Chinese postmenopausal women. Ann Nutr Metab 2014;64:13-9.

Farhat GN, Cauley JA. The link between osteoporosis and cardiovascular disease. Clin Cases Miner Bone Metab 2008;5:19-34.

Estrada K, Styrkarsdottir U, Evangelou E, Hsu YH, Duncan EL, Ntzani EE, et al. Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet 2012;44:491-501.

Bolland MJ, Avenell A, Baron JA, Grey A, MacLennan GS, Gamble GD, et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: Meta-analysis. BMJ 2010;341:c3691.

den Uyl D, Nurmohamed MT, van Tuyl LH, Raterman HG, Lems WF. (Sub)clinical cardiovascular disease is associated with increased bone loss and fracture risk; A systematic review of the association between cardiovascular disease and osteoporosis. Arthritis Res Ther 2011;13:R5.